Related references
Note: Only part of the references are listed.Early Serum HBsAg Drop: A Strong Predictor of Sustained Virological Response to Pegylated Interferon Alfa-2a in HBeAg-Negative Patients
Rami Moucari et al.
HEPATOLOGY (2009)
Hepatitis B Virus Surface Antigen Levels: A Guide to Sustained Response to peginterferon alfa-2a in HBeAg-Negative Chronic Hepatitis B
Maurizia Rossana Brunetto et al.
HEPATOLOGY (2009)
Benefits and Risks of Interferon Therapy for Hepatitis B
Robert Perrillo
HEPATOLOGY (2009)
Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b
Erik H. C. J. Buster et al.
GASTROENTEROLOGY (2008)
Virological and biochemical response in patients with HBeAG-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) with or without lamivudine: Results of 4-year follow-up
P. Marcellin et al.
JOURNAL OF HEPATOLOGY (2008)
A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B
Robert G. Gish et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
F. Bonino et al.
GUT (2007)
HBsAg seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long-term follow-up
Chia-Ming Chu et al.
HEPATOLOGY (2007)
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
P Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy
B Werle-Lapostolle et al.
GASTROENTEROLOGY (2004)
Share Paper
